NCT04205227 - ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Biotech Hunter

Enrollment

137

Participants

Timeline

Start Date

February 18, 2020

Primary Completion Date

January 1, 2026

Study Completion Date

March 31, 2026

Conditions

CancerMelanomaOvary CancerPancreatic CancerSolid Tumor

Interventions

DRUG

ENB003

ENB003 is selective Endothelin B Receptor Antagonist

DRUG

Pembrolizumab

anti-PD1

Trial Locations (5)

Kinghorn-St Vincent's Hospital, Darlinghurst

Blacktown Oncology, Blacktown

Border Medical Oncology, Albury

MD Anderson Cancer Center, Houston

Cedars Sinai-The Angeles Clinic, Los Angeles